Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel V Alavi

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Expert Opinion on Therapeutic Targets|May 8, 2026
Targeting the OPA1 pathway in autosomal dominant optic atrophy (ADOA): 25 years from gene discovery to therapeutic strategyMarcel V Alavi
Advances in Experimental Medicine and Biology|October 3, 2015
Aging and VisionMarcel V Alavi
ACS Chemical Biology|October 21, 2021
OMA1 High-Throughput Screen Reveals Protease Activation by Kinase InhibitorsMarcel V Alavi
International Journal of Cancer|February 5, 2019
Targeted OMA1 therapies for cancerMarcel V Alavi
Biochimica Et Biophysica Acta. Molecular Cell Research|August 17, 2021
Tau phosphorylation and OPA1 proteolysis are unrelated events: Implications for Alzheimer's DiseaseMarcel V Alavi
Biochimica Et Biophysica Acta. Proteins and Proteomics|November 1, 2020
OMA1-An integral membrane protease?Marcel V Alavi
Pharmacological Research|January 9, 2022
Recent advances in, and challenges of, designing OMA1 drug screensMarcel V Alavi
Molecular Neurodegeneration|September 27, 2013
Dominant optic atrophy, OPA1, and mitochondrial quality control: understanding mitochondrial network dynamicsMarcel V Alavi, Nico Fuhrmann
Experimental Eye Research|August 1, 2007
Identification of genes that are linked with optineurin expression using a combined RNAi--microarray approachNicole Weisschuh, Marcel V Alavi, Michael Bonin, et al.
Current Topics in Membranes|November 28, 2015
Type IV Collagens and Basement Membrane Diseases: Cell Biology and Pathogenic MechanismsMao Mao, Marcel V Alavi, Cassandre Labelle-Dumais, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Expert Opinion on Therapeutic Targets|May 8, 2026
Targeting the OPA1 pathway in autosomal dominant optic atrophy (ADOA): 25 years from gene discovery to therapeutic strategyMarcel V Alavi
Advances in Experimental Medicine and Biology|October 3, 2015
Aging and VisionMarcel V Alavi
ACS Chemical Biology|October 21, 2021
OMA1 High-Throughput Screen Reveals Protease Activation by Kinase InhibitorsMarcel V Alavi
International Journal of Cancer|February 5, 2019
Targeted OMA1 therapies for cancerMarcel V Alavi
Biochimica Et Biophysica Acta. Molecular Cell Research|August 17, 2021
Tau phosphorylation and OPA1 proteolysis are unrelated events: Implications for Alzheimer's DiseaseMarcel V Alavi
Biochimica Et Biophysica Acta. Proteins and Proteomics|November 1, 2020
OMA1-An integral membrane protease?Marcel V Alavi
Pharmacological Research|January 9, 2022
Recent advances in, and challenges of, designing OMA1 drug screensMarcel V Alavi
Molecular Neurodegeneration|September 27, 2013
Dominant optic atrophy, OPA1, and mitochondrial quality control: understanding mitochondrial network dynamicsMarcel V Alavi, Nico Fuhrmann
Experimental Eye Research|August 1, 2007
Identification of genes that are linked with optineurin expression using a combined RNAi--microarray approachNicole Weisschuh, Marcel V Alavi, Michael Bonin, et al.
Current Topics in Membranes|November 28, 2015
Type IV Collagens and Basement Membrane Diseases: Cell Biology and Pathogenic MechanismsMao Mao, Marcel V Alavi, Cassandre Labelle-Dumais, et al.
Pageof 3